Menu

Fish Oil May Slow Schizophrenia

Omega-3 supplementation reduced progression rates among people with early-stage symptoms of schizophrenia, according to a small trial.

Aug 13, 2015
Jef Akst

WIKIMEDIA, ODDMAN47Seven years ago, investigators enrolled 81 people aged 13 to 25 with early signs of schizophrenia in a clinical trial to test the effects of omega-3 fish oil pills. A paper published this week (August 11) in Nature Communications reported on 71 of those participants, pointing to a notable benefit of the supplements: only 10 percent of those taking fish oils ultimately developed schizophrenia, compared with 40 percent of the placebo group.

“I don’t want to sound like a cynic or a skeptic, but it’s almost too good to be true,” psychiatrist Jeffrey Lieberman of Columbia University Medical Center in New York City who was not involved in the study told ScienceNews.

Schizophrenia usually starts to manifest in the first 20 to 30 years of life, with minor delusions and paranoid thoughts often occurring in the teenage years or younger. But only about a third of people who present with such early symptoms eventually develop psychosis, New Scientist reported. After researchers found that the blood cells of schizophrenia patients have lower levels of omega-3 fatty acids than those of healthy controls, scientists in the field began to investigate the possibility that supplementing these compounds could treat the disorder. Results of early trials have been mixed, but this latest study points to the potential benefit of fatty acids if taken early enough.

“Schizophrenia is a major cause of disability, but early treatment has been linked to better outcomes,” coauthor Paul Amminger at the University of Melbourne in Australia told The Guardian. “Our study gives hope that there may be alternatives to antipsychotic medication.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.